Study Design: One-year follow-up of a randomized clinical trial.
Objectives: Examine voluntary dietary compliance 1 year following the cessation of the intervention and the persistence of accrued benefits related to neuropathic pain and mood.
Setting: Outpatient rehabilitation program within the Niagara region.
Methods: Five individuals (4 female, 1 male; age 50.6 ± 11.8 years) with chronic SCI (C5-L3; ISNCSCI: A-D; 7-40 years post injury) who had previously completed a 3-month anti-inflammatory diet were reassessed after 1 year for measures related to dietary compliance, CES-D scores of depression, and NPQ scores of neuropathic pain.
Results: There was a significant reduction in diet compliance at the 1-year follow-up in comparison to the end of the dietary intervention at 3 months (92.6% versus 43.0%, < 0.01). CES-D scores showed a trend toward an increase from 3 months to follow-up (8.0 versus 21.4, = .10) whereby follow-up CES-D scores were no longer statistically different from baseline ( = 0.74). Sensory NPQ scores showed no significant change from 3 months to follow-up (25.2 versus 29.1, = 0.42) and remained significantly lower than baseline ( = 0.02). Affective NPQ scores were significantly increased from 3 months to follow-up (27.7 versus 40.1, = 0.05). Sensitivity NPQ scores showed no significant change from 3 month to follow-up (28.2 versus 33.5, = 0.34), but returned to a score that was statistically similar to baseline ( = 0.15).
Conclusions: These results emphasize the importance of continued compliance to a diet with anti-inflammatory properties for the purposes of maintaining benefits related to mood and neuropathic pain in individuals with SCI.
Sponsorship: This study was supported by the Ontario Neurotrauma Foundation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212583 | PMC |
| http://dx.doi.org/10.1038/s41394-018-0131-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacological modulation of Sigma-1 receptor ameliorates pathological neuroinflammation in rats with diabetic neuropathic pain via the AKT/GSK-3β/NF-κB pathway.
Brain Res Bull
January 2025
Department of Pharmacology, Shaanxi University of Chinese Medicine, Xianyang, 712046, PR China; Key Laboratory of Pharmacodynamic Mechanism and Material Basis of Traditional Chinese Medicine, Shaanxi Administration of Traditional Chinese Medicine, Xianyang 712046, PR China. Electronic address:
Diabetic neuropathic pain (DNP) is a common complication of diabetes mellitus (DM) and is characterized by spontaneous pain and neuroinflammation. The Sigma-1 receptor (Sig-1R) has been proposed as a target for analgesic development. It is an important receptor with anti-inflammatory properties and has been found to regulate DNP.
View Article and Find Full Text PDFReducing IgG accumulation via neonatal Fc receptor (FcRn) blockade relieves neuropathic pain.
Brain Behav Immun
January 2025
Laboratories of Neuroimmunology, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address:
Preclinical and clinical studies have established that autoreactive immunoglobulin G (IgG) can drive neuropathic pain. We recently demonstrated that sciatic nerve chronic constriction injury (CCI) in male and female mice results in the production of pronociceptive IgG, which accumulates around the lumbar region, including within the dorsal root ganglia (DRG) and spinal cord, facilitating the development of neuropathic pain. These data raise the intriguing possibility that neuropathic pain may be alleviated by reducing the accumulation of IgG.
View Article and Find Full Text PDFAn Algorithmic Overview of Advanced Pain Therapies: A Narrative Review.
Curr Pain Headache Rep
January 2025
Department of Pain Medicine, Division of Anesthesiology, Critical Care & Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Purpose Of Review: Quickly referenceable, streamlined, algorithmic approaches for advanced pain management are lacking for patients, trainees, non-pain specialists, and interventional specialists. This manuscript aims to address this gap by proposing a comprehensive, evidence-based algorithm for managing neuropathic, nociceptive, and cancer-associated pain. Such an algorithm is crucial for pain medicine education, offering a structured approach for patient care refractory to conservative management.
View Article and Find Full Text PDFPeripheral neuropathy: from guidelines to clinical practise.
Curr Opin Oncol
January 2025
Department of Hematology, Oncology and Palliative Medicine, Ernst von Bergmann Hospital Potsdam, Potsdam.
Purpose Of Review: Chemotherapy-induced peripheral neuropathy (CIPN) is a substantial adverse effect of anticancer therapy. No effective preventive strategies are established in clinical routine, although some forms of cryotherapy or compression therapy seem to be promising. CIPN is difficult to grade objectively and has mostly relied on a clinician- or patient-based rating that is subjective and not easily reproducible.
View Article and Find Full Text PDFEarly-life adversity as a predictor of fibromyalgia syndrome: the central role of perceived stress over endocrine stress indicators.
Pain
January 2025
Department of General Internal Medicine and Psychosomatics, Heidelberg University, Heidelberg, Germany.
This study investigates the associations between early childhood adversities, stress perception, and fibromyalgia syndrome (FMS). Although the interconnection between dysregulated stress systems and FMS is well documented, the interconnection between early adversities and FMS remains less understood. This study explores the relationship of early-life stress and FMS by examining its mediation through perceived stress, and acute and chronic endocrine stress indicators.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!